ArticleScientific reports2026
Development of an influenza D virus with an eight- or nine-segment genome.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Influenza D virus (IDV) contains seven genome segments. The M and NS segments are regulated via splicing to express two proteins each (P42 and M1 from the M segment and NS1 and NS2 from the NS segment). Previously, we created an eight-segment IDV by separating the NS1 and NS2 genes into independent monocistronic segments. In this study, we designed another eight-segment IDV with two divided M segments, transcribing either P42 or M1 mRNA independently. Specifically, we constructed two plasmids for reverse genetics: one for viral RNA (vRNA) synthesis of the P42 segment with silent mutations at the splicing donor site and one for vRNA synthesis of the M1 segment with deletion of the intron in the M segment. We successfully created the virus via reverse genetics using these two segments and six other vRNA synthesis plasmids (PB2, PB1, P3, HEF, NP, and NS). Furthermore, we generated a nine-segment IDV including the P42, M1, NS1, and NS2 segments. These systems enable independent functional and interactive analyses of M and NS segment-encoded proteins for viral infectivity. Additionally, the eight- and nine-segment IDVs exhibited significantly reduced replication in cell culture compared with wild-type IDV, suggesting a strategy for attenuated live vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.